| scholarly article | Q13442814 |
| P50 | author | Ray Borrow | Q64500634 |
| P2093 | author name string | Jamie Findlow | |
| Christoph M Tang | |||
| Rachel M Exley | |||
| Jay Lucidarme | |||
| Lionel Tan | |||
| P2860 | cites work | Complete Genome Sequence of Neisseria meningitidis Serogroup B Strain MC58 | Q22065549 |
| Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491 | Q22122399 | ||
| Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086 | Q24654235 | ||
| Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates | Q27653843 | ||
| Neisseria meningitidis: an overview of the carriage state | Q28277386 | ||
| The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement | Q28474974 | ||
| NeMeSys: a biological resource for narrowing the gap between sequence and function in the human pathogen Neisseria meningitidis | Q28749761 | ||
| Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease | Q58301797 | ||
| Naturally occurring insertional inactivation of theporAgene ofNeisseria meningitidisby integration of IS1301 | Q63371254 | ||
| Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. | Q64901018 | ||
| Capsule phase variation in Neisseria meningitidis serogroup B by slipped-strand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease | Q71538870 | ||
| Distinct mechanisms of interactions of Opc-expressing meningococci at apical and basolateral surfaces of human endothelial cells; the role of integrins in apical interactions | Q71669928 | ||
| Functional significance of factor H binding to Neisseria meningitidis | Q83918204 | ||
| Infectious diseases associated with complement deficiencies | Q30450183 | ||
| Meningococcal genetic variation mechanisms viewed through comparative analysis of serogroup C strain FAM18. | Q33274203 | ||
| Complement regulators and inhibitory proteins | Q33386110 | ||
| The influence of IS1301 in the capsule biosynthesis locus on meningococcal carriage and disease | Q33535924 | ||
| Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005 | Q33729202 | ||
| Independent evolution of the core and accessory gene sets in the genus Neisseria: insights gained from the genome of Neisseria lactamica isolate 020-06. | Q33752108 | ||
| Update on meningococcal disease with emphasis on pathogenesis and clinical management | Q33812435 | ||
| Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. | Q34537851 | ||
| Epidemic meningitis, meningococcaemia, and Neisseria meningitidis | Q34644525 | ||
| Complete genome sequence of Neisseria gonorrhoeae NCCP11945. | Q34790002 | ||
| Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease | Q36009616 | ||
| Deletion of the meningococcal fetA gene used for antigen sequence typing of invasive and commensal isolates from Germany: frequencies and mechanisms | Q36098684 | ||
| A universal vaccine for serogroup B meningococcus | Q36101910 | ||
| Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870 | Q36370598 | ||
| Defining targets for complement components C4b and C3b on the pathogenic neisseriae | Q36422066 | ||
| The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance | Q36470692 | ||
| The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica | Q36472571 | ||
| Whole-genome comparison of disease and carriage strains provides insights into virulence evolution in Neisseria meningitidis | Q36491155 | ||
| A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies | Q36699790 | ||
| Interactions between Neisseria meningitidis and the complement system. | Q36775957 | ||
| Vaccine potential of the Neisseria meningitidis 2086 lipoprotein | Q37115883 | ||
| Complement evasion strategies of pathogens-acquisition of inhibitors and beyond | Q37499399 | ||
| Genome flexibility in Neisseria meningitidis | Q37499451 | ||
| Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis | Q38326601 | ||
| Variation of the factor H-binding protein of Neisseria meningitidis | Q38350786 | ||
| Comparative genome biology of a serogroup B carriage and disease strain supports a polygenic nature of meningococcal virulence | Q39667409 | ||
| Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus | Q39981028 | ||
| Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine | Q41012990 | ||
| Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. | Q41825787 | ||
| Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales | Q41845489 | ||
| Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection | Q41966979 | ||
| Transcellular passage of Neisseria meningitidis across a polarized respiratory epithelium | Q42428389 | ||
| Two-partner secretion systems of Neisseria meningitidis associated with invasive clonal complexes | Q42664149 | ||
| Global epidemiology of meningococcal disease. | Q44677055 | ||
| Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis | Q46777542 | ||
| Contribution of genes from the capsule gene complex (cps) to lipooligosaccharide biosynthesis and serum resistance in Neisseria meningitidis. | Q48084641 | ||
| Characterization of ST-4821 complex, a unique Neisseria meningitidis clone. | Q50857953 | ||
| Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease | Q56880540 | ||
| Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity | Q57531180 | ||
| P433 | issue | 6 | |
| P921 | main subject | Neisseria meningitidis | Q154625 |
| P304 | page(s) | 1002-1014 | |
| P577 | publication date | 2011-04-20 | |
| P1433 | published in | Clinical and Vaccine Immunology | Q5133811 |
| P1476 | title | Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein | |
| P478 | volume | 18 |
| Q57588792 | A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial |
| Q36521563 | A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine |
| Q38132262 | A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn? |
| Q38235428 | A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants |
| Q38200261 | A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty |
| Q37994540 | Bexsero: a multicomponent vaccine for prevention of meningococcal disease. |
| Q35965207 | Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine |
| Q98905790 | Broad vaccine protection against Neisseria meningitidis using factor H binding protein |
| Q35708801 | Characterization of invasive Neisseria meningitidis strains from Québec, Canada, during a period of increased serogroup B disease, 2009-2013: phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets |
| Q36936278 | Conservation of meningococcal antigens in the genus Neisseria |
| Q34916886 | Distinct binding and immunogenic properties of the gonococcal homologue of meningococcal factor h binding protein |
| Q37124721 | Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses? |
| Q30234958 | Emerging experience with meningococcal serogroup B protein vaccines |
| Q92951277 | Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp) |
| Q36684761 | Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined |
| Q37267074 | Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis |
| Q38674983 | Frequent capsule switching in 'ultra-virulent' meningococci - Are we ready for a serogroup B ST-11 complex outbreak? |
| Q42287840 | Functional impacts of the diversity of the meningococcal factor H binding protein |
| Q45097394 | Gene variability and degree of expression of vaccine candidate factor H binding protein in clinical isolates of Neisseria meningitidis |
| Q37469617 | Genetic distribution of noncapsular meningococcal group B vaccine antigens in Neisseria lactamica |
| Q92929424 | Genetic variability of Polish serogroup B meningococci (2010-2016) including the 4CMenB vaccine component genes |
| Q35108361 | Genotypic analysis of meningococcal factor h-binding protein from non-culture clinical specimens |
| Q33602953 | Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model |
| Q35845900 | Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009. |
| Q34376049 | LOS oligosaccharide modification enhances dendritic cell responses to meningococcal native outer membrane vesicles expressing a non-toxic lipid A |
| Q37002310 | Meningococcal Factor H Binding Protein Vaccine Antigens with Increased Thermal Stability and Decreased Binding of Human Factor H. |
| Q33609246 | Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents. |
| Q34376170 | Meningococcal disease and the complement system |
| Q35773926 | Molecular Engineering of Ghfp, the Gonococcal Orthologue of Neisseria meningitidis Factor H Binding Protein |
| Q41673949 | Neisseria cinerea expresses a functional factor H binding protein which is recognised by immune responses elicited by meningococcal vaccines. |
| Q38183156 | Neisseria meningitidis B vaccines: recent advances and possible immunization policies. |
| Q38363907 | Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen. |
| Q92743045 | Neisseria meningitidis-Induced Caspase-1 Activation in Human Innate Immune Cells Is LOS-Dependent |
| Q37690815 | New versus old meningococcal group B vaccines: how the new ones may benefit infants & toddlers |
| Q39466320 | Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment |
| Q52361221 | Prevalence and genetic characteristics of 4CMenB and rLP2086 vaccine candidates among Neisseria meningitidis serogroup B strains, China. |
| Q40274755 | Prevalence of factor H Binding Protein sub-variants among Neisseria meningitidis in China |
| Q26995760 | Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease |
| Q40287703 | Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial |
| Q38335257 | The Long Road to an Effective Vaccine for Meningococcus Group B (MenB). |
| Q35989852 | The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens |
| Q38677309 | The next chapter for group B meningococcal vaccines |
| Q35936064 | The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci |
| Q38864097 | Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae |
| Q38538836 | Vaccines for prevention of group B meningococcal disease: Not your father's vaccines |
| Q42223921 | Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway |
| Q36911374 | ZnuD, a potential candidate for a simple and universal Neisseria meningitidis vaccine |
| Q37130358 | fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations. |
Search more.